A Study Comparing the Effectiveness of Rivaroxaban versus the Standard of Care (SOC) in Low Risk Pulmonary Embolism (LRPE) US Veterans Health Administration (VHA) Patients

Trial Profile

A Study Comparing the Effectiveness of Rivaroxaban versus the Standard of Care (SOC) in Low Risk Pulmonary Embolism (LRPE) US Veterans Health Administration (VHA) Patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Sep 2017

At a glance

  • Drugs Rivaroxaban (Primary) ; Heparin; Low molecular weight heparin; Warfarin
  • Indications Pulmonary embolism
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 29 Sep 2017 New trial record
    • 30 Aug 2017 Results presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top